Tools   Select Another Resource Report Type

http://www.itor-ghs.org/biorepository.php

From the type of mutation causing cancer to specific gene expression levels, genetic biomarkers are becoming an indispensable tool for developing new treatment models for cancer. The ITOR Biorepository Services tissue bank initiatives are critical to the continued development of an organized research infrastructure that will attract leading biotechnology and pharmaceutical companies interested in developing the next generation of cancer therapies. Ultimately, by linking the laboratory and clinical settings through innovative research investigations, USC, Greenville Hospital System University Medical Center, and private partners can identify the most novel ways to find and couple these biomarkers to patient drug trials and eventually, the most effective treatments & cures for cancer. The ITOR Biorepository Services Department ����?����������?? in conjunction with the Greenville Hospital System''s surgical oncologists, pathologists and staff ����?����������?? have developed tissue bank sample processing guidelines for frozen tissue, fresh tissue and peripheral blood and include flash freezing in liquid nitrogen within 15 minutes of harvest to maximize cell viability for basic science research. The department has a dedicated staff, including two research nurses and a data coordinator, which facilitate the logistics of tissue handling and submit outcomes data on participating patients. The ITOR Biorepository staff is in the process of adopting a universal consent for all patients of the Greenville Hospital System to have the option of donating excess tissue for research, should they desire. ITOR of GHS has several tissue-based patient initiatives & programs under development and ongoing. At the forefront of cancer care are two specific programs, Total Cancer Care and Caris Target Now.

Proper citation: ITOR Biorepository Services (RRID:SCR_004191) Copy   

•   Source: SciCrunch Registry

http://www.liv.ac.uk/ltb/

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. It has been incorporated with the LBIH Biobank. The Liverpool Tissue Bank (LTB) collects biological samples (tissue surplus to diagnostic requirement and blood) from patients undergoing surgery or biopsy procedure for the treatment and diagnosis of a wide variety of medical conditions. The main focus of the LTB is collecting samples from patients where cancer is a confirmed or likely diagnosis. These samples are banked to provide an invaluable resource for research groups investigating the molecular mechanisms involved in a range of medical conditions with the aim of devising new treatments and therapies. The Liverpool Tissue Bank (LTB) was formerly known as the Cancer Tissue Bank Research Centre (CTBRC) and changed to the LTB in late 2009. The Tissue Bank was established in 1991 from a charitable donation by the Candis Club, the charitable arm of Candis Magazine. It is a University of Liverpool resource located within the Department of Pathology, School of Cancer Studies. The LTB operates a cost recovery scheme where a charge is made to researchers to cover the costs involved in the collection, storage and processing of biosamples.

Proper citation: Liverpool Tissue Bank (RRID:SCR_004143) Copy   

•   Source: SciCrunch Registry

http://cancer.case.edu/sharedresources/tissue/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. The Case Comprehensive Cancer Center''s Biorepository and Tissue Processing Core Facility (BTPC) serves two primary functions: 1. To build an inventory of remnant human tissues, blood and other body fluids (collectively termed biospecimens) targeted towards cancer and other medical research, for later assignment to investigators; and 2. To provide long term, controlled storage of biospecimens for specific researchers. These samples are for research purposes only and may not be used for clinical diagnosis or implantation into humans. Clinical information relating to the samples and donors are collected and maintained in a secure database. Samples and data are de-identified or de-linked before release to the researcher unless he/she has specific IRB approval to gain access to this information. Remnant biospecimens are prospectively collected from surgical procedures, autopsies and clinical laboratories for the BTPC by the Human Tissue Procurement Facility (HTPF), which operates under UH-IRB Protocol 01-02-45. Blood and bone marrow specimens are collected for the BTPC by the Hematopoietic Stem Cell Core Facility (HSCC), which operates under UH-IRB Protocol 09-90-195. The Division of Surgical Pathology at University Hospitals Case Medical Center (UHCMC) has clinical archives of paraffin blocks that can be made available through the BTPC for retrospective research studies under the approval of the Vice Chair for Clinical Affairs at UHCMC. Surgical Pathologists associated with the BTPC are responsible for determining which blocks can be made available and how much material can be removed from the blocks. Types of Tissue Available * Malignant, benign, diseased, normal and normal human tissues * Normal adjacent tissues available paired with tumor specimens in many cases * Tissues are collected from over 50 anatomic sites * Frozen specimens, OCT-embedded and paraffin-embedded tissues * Large array of paraffin-embedded specimens from clinical archives of paraffin blocks and QC research blocks maintained by the HTPF * Peripheral blood and bone marrow samples from initial visits and follow-up procedures are processed to obtain serum and cell fractions for storage * No samples are collected from individuals with known infectious illnesses * Fetal biospecimens are not collected due to state and local statutes

Proper citation: Case Comprehensive Cancer Center Biorepository and Tissue Processing Core Facility (RRID:SCR_004382) Copy   

•   Source: SciCrunch Registry

http://www.mycancergenome.org/

A freely available online personalized cancer medicine knowledge resource for physicians, patients, caregivers and researchers that gives up-to-date information on what mutations make cancers grow and related therapeutic implications, including available clinical trials. It is a one-stop tool that matches tumor mutations to therapies, making information accessible and convenient for busy clinicians.

Proper citation: My Cancer Genome (RRID:SCR_004140) Copy   

•   Source: SciCrunch Registry

http://www.startthecure.com/clinical_tumor_bank.php

Biospecimen repository for tumor specimens, available to all researchers actively engaged in cancer research whether they are in University, Academic, or Pharmaceutical industry, with a goal to accelerate the discovery and development of new agents for the treatment and cure of cancer. The START tumor bank was created to make tumor tissue gifted by patients receiving care or treatment at The START Center available to all researchers involved in developing a better understanding of the biology of cancer or those engaged in the discovery of new therapies. The START Tumor Bank is a department within the PK Department and handles skin and tumor biopsies required by clinical trial protocols. A member of the PK Department is present during biopsy procedures for immediate processing of the sample for the trial. Additionally, the Tumor Bank collects and banks the tumor tissues of patients who consent. This tissue is then stored for future use by researchers developing new therapies.

Proper citation: START Tumor Bank (RRID:SCR_004258) Copy   

•   Source: SciCrunch Registry

https://www.bips-institut.de/en/research/cancer-registry.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023. A population based database collecting incident cases of cancer diagnosed since January 1998 in the population of the Federal state of Bremen. The Registry provides data for the analysis of * age specific time trends and geographical patterns of cancer incidence in men and women * cancer causes (e.g. work-related, environmental and personal risk factors) * epidemiological evaluation of screening programs * survival analysis of cancer patients. Since the incidence year of 2001, the Registry has a completeness level of > 95 %, based on expected values provided by the Robert Koch Institute.

Proper citation: Bremen Cancer Registry (RRID:SCR_004093) Copy   

•   Source: SciCrunch Registry

http://www.hemonc.org

Medical wiki of interventions, regimens, and general information relevant to fields of hematology and oncology. Knowledge base for hematology and oncology providers, containing details about hematology/oncology drugs and treatment regimens. Any healthcare professional can sign up to contribute. Acuracy and completeness of content is overseen by Editorial Board.

Proper citation: HemOnc Knowledgebase (RRID:SCR_023436) Copy   

•   Source: SciCrunch Registry

https://grail.com/clinical-studies/ccga-study/

Prospective, observational, longitudinal, study designed to characterize landscape of genomic cancer signals in blood of people with and without cancer. Sudy includes people in the USA and Canada who had cancer at the time of enrollment, newly diagnosed, and not yet received treatment, and people who did not have known cancer diagnosis.

Proper citation: Circulating Cell-free Genome Atlas project (RRID:SCR_023878) Copy   

•   Source: SciCrunch Registry

https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html

Website describing International Classification of Diseases-Oncology codes that corresponds to different cancer sites in the Surveillance, Epidemiology, and End Results (SEER) registry.

Proper citation: NCI Site Recode ICD-O-3/WHO 2008 Definition (RRID:SCR_024687) Copy   

•   Source: SciCrunch Registry

http://www.medinadiscovery.com/

A non-profit research center established through a public-private alliance between the Regional government of Andalusia, the pharmaceutical company Merck Sharp & Dohme Spain S.A. (MSD), and the University of Granada, that is focused on: # Discovery of new compounds and therapies as new leads for drug development # Contract Research Services: High throughput screening services for lead discovery, ADME/TOX, bioanalysis and metabolomics MEDINA offers 1) natural products screening services for lead discovery on therapeutic targets developed by the customers and 2) compound profiling services for their drug candidates, using a counterscreening panel designed to determine potential risks in cardiovascular safety and drug-drug interactions.

Proper citation: MEDINA Foundation (RRID:SCR_004079) Copy   

•   Source: SciCrunch Registry

http://www.zfatlas.psu.edu/

Atlas containing 2- and 3-dimensional, anatomical reference slides of the lifespan of the zebrafish to support research and education worldwide. Hematoxylin and eosin histological slides, at various points in the lifespan of the zebrafish, have been scanned at 40x resolution and are available through a virtual slide viewer. 3D models of the organs are reconstructed from plastic tissue sections of embryo and larvae. The size of the zebrafish, which allows sections to fall conveniently within the dimensions of the common 1 x 3 glass slide, makes it possible for this anatomical atlas to become as high resolution as for any vertebrate. That resolution, together with the integration of histology and organ anatomy, will create unique opportunities for comparisons with both smaller and larger model systems that each have their own strengths in research and educational value. The atlas team is working to allow the site to function as a scaffold for collaborative research and educational activity across disciplines and model organisms. The Zebrafish Atlas was created to answer a community call for a comprehensive, web-based, anatomical and pathological atlas of the zebrafish, which has become one of the most widely used vertebrate animal models globally. The experimental strengths of zebrafish as a model system have made it useful for a wide range of investigations addressing the missions of the NIH and NSF. The Zebrafish Atlas provides reference slides for virtual microscopic viewing of the zebrafish using an Internet browser. Virtual slide technology allows the user to choose their own field of view and magnification, and to consult labeled histological sections of zebrafish. We are planning to include a complete set of embryos, larvae, juveniles, and adults from approximately 25 different ages. Future work will also include a variety of comparisons (e.g. normal vs. mutant, normal vs. diseased, multiple stages of development, zebrafish with other organisms, and different types of cancer)., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Zebrafish Atlas (RRID:SCR_006722) Copy   

•   Source: SciCrunch Registry

http://www.lincsproject.org/

Project to create network based understanding of biology by cataloging changes in gene expression and other cellular processes when cells are exposed to genetic and environmental stressors. Program to develop therapies that might restore pathways and networks to their normal states. Has LINCS Data Coordination and Integration Center and six Data and Signature Generation Centers: Drug Toxicity Signature Generation Center, HMS LINCS Center, LINCS Center for Transcriptomics, LINCS Proteomic Characterization Center for Signaling and Epigenetics, MEP LINCS Center, and NeuroLINCS Center.

Proper citation: LINCS Project (RRID:SCR_016486) Copy   

•   Source: SciCrunch Registry

http://cahub.cancer.gov/about/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented July 5, 2018. A national center for biospecimen science and standards to advance cancer research and treatment. It was created in response to the critical and growing need for high-quality, well-documented biospecimens for cancer research. The initiative builds on resources already developed by the NCI, including the Biospecimen Research Network and the NCI Best Practices for Biospecimen Resources, both of which were developed to address challenges around standardization of the collection and dissemination of quality biospecimens. caHUB will develop the infrastructure for collaborative biospecimen research and the production of evidence-based biospecimen standard operating procedures.

Proper citation: caHUB (RRID:SCR_009657) Copy   

•   Source: SciCrunch Registry

http://ccmi.org

Initiative to enable cancer discovery and treatment based on complete elucidation of molecular networks underlying cancer. CCMI leverages advanced interaction mapping and computational facilities to generate and analyze cancer networks.

Proper citation: Cancer Cell Map Initiative (RRID:SCR_023043) Copy   

•   Source: SciCrunch Registry

http://www.grc.nia.nih.gov/

A research program of the NIA which focuses on neuroscience, aging biology, and translational gerontology. The central focus of the program's research is understanding age-related changes in physiology and the ability to adapt to environmental stress, and using that understanding to develop insight about the pathophysiology of age-related diseases. The IRP webpage provides access to other NIH resources such as the Biological Biochemical Image Database, the Bioinformatics Portal, and the Baltimore Longitudinal Study of Aging., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Intramural Research Program (RRID:SCR_012734) Copy   

•   Source: SciCrunch Registry

http://oncokb.org

Precision oncology knowledge base which contains information about the effects and treatment implications of specific cancer gene alterations. OncoKB contains detailed information about specific alterations in 418 cancer genes. Each variant entry contains biological effect, prevalence, prognostic information, and treatment implications. Information is curated from various sources, such as guidelines from the FDA, ClinicalTrials.gov, and scientific literature by a network of clinical fellows, research fellows, and faculty members at Memorial Sloan Kettering Cancer Center.

Proper citation: OncoKB (RRID:SCR_014782) Copy   

•   Source: SciCrunch Registry

http://galaxy.cineca.it/fusion/main

Portal provides an easy access to a comprehensive database designed for storing, displaying and annotating gene fusion events detected from NGS data. It can query a database of somatic fusion genes events predicted and annotated starting from paired-end RNA-seq data.

Proper citation: LiGeA (RRID:SCR_015940) Copy   

•   Source: SciCrunch Registry

https://www.mitochondriasci.com/mitochondria-related-diseases.html

Creative Biogene provides comprehensive range of services and products to assist researchers in mitochondrial assays and studies. Service to validate and explore pathogenesis of mitochondria associated diseases and possible interventions.

Proper citation: Creative Biogene Mitochondria Related Diseases (RRID:SCR_022080) Copy   

•   Source: SciCrunch Registry

https://pdc.cancer.gov/pdc/

Portal to make cancer related proteomic datasets easily accessible to public. Facilitates multiomic integration in support of precision medicine through interoperability with other resources. Developed to advance our understanding of how proteins help to shape risk, diagnosis, development, progression, and treatment of cancer. One of several repositories within NCI Cancer Research Data Commons which enables researchers to link proteomic data with other data sets (e.g., genomic and imaging data) and to submit, collect, analyze, store, and share data throughout cancer data ecosystem. PDC provides access to highly curated and standardized biospecimen, clinical, and proteomic data, intuitive interface to filter, query, search, visualize and download data and metadata. Provides common data harmonization pipeline to uniformly analyze all PDC data and provides advanced visualization of quantitative information. Cloud based (Amazon Web Services) infrastructure facilitates interoperability with AWS based data analysis tools and platforms natively. Application programming interface (API) provides cloud-agnostic data access and allows third parties to extend functionality beyond PDC. Structured workspace that serves as private user data store and also data submission portal. Distributes controlled access data, such as patient-specific protein fasta sequence databases, with dbGaP authorization and eRA Commons authentication.

Proper citation: Proteomic Data Commons (RRID:SCR_018273) Copy   

•   Source: SciCrunch Registry

https://portal.imaging.datacommons.cancer.gov

Portal for finding and analyzing cancer imaging data. Part of Cancer Research Data Commons to support cancer imaging research. Provides cloud based access to medical imaging data and library of analytical tools and workflows to share, analyze, and visualize multi modal imaging data from both clinical and basic cancer research studies.

Proper citation: NCI Imaging Data Commons (RRID:SCR_019127) Copy   

•   Source: SciCrunch Registry